Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Short term Debt (2016 - 2023)

Historic Short term Debt for Ligand Pharmaceuticals (LGND) over the last 9 years, with Q1 2023 value amounting to $76.8 million.

  • Ligand Pharmaceuticals' Short term Debt changed N/A to $76.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was $76.8 million, marking a year-over-year change of. This contributed to the annual value of $76.7 million for FY2022, which is N/A changed from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Short term Debt stood at $76.8 million for Q1 2023.
  • Ligand Pharmaceuticals' 5-year Short term Debt high stood at $115.0 million for Q2 2022, and its period low was $26.8 million during Q1 2019.
  • Its 3-year average for Short term Debt is $66.5 million, with a median of $76.6 million in 2022.
  • Over the last 5 years, Ligand Pharmaceuticals' Short term Debt had its largest YoY gain of 8824.16% in 2019, and its largest YoY loss of 9325.0% in 2019.
  • Ligand Pharmaceuticals' Short term Debt (Quarter) stood at $27.1 million in 2019, then soared by 183.14% to $76.7 million in 2022, then grew by 0.12% to $76.8 million in 2023.
  • Its last three reported values are $76.8 million in Q1 2023, $76.7 million for Q4 2022, and $76.6 million during Q3 2022.